Prostate Cancer News
News on Prostate Cancer continually updated from thousands of sources around the net.
49 min ago | 5NEWSonline.com
In conjunction with Prostate Cancer Awareness Month this September, doctors at Sparks Health Systems are teaming up to teach people about prostate cancer. Prostate cancer is the second most deadly type of cancer for men.
2 hrs ago | MyHighPlains.com
Prostate cancer is the most common cancer in men. Thanks to aggressive screening the mortality rate for prostate cancer decreased.
4 hrs ago | Medical News
Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who have rising Prostate Specific Antigen levels and no detectable metastases.
From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, New York; University of Washington School of Medicine, Seattle, Washington; and UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. Grant Support: This work was supported by the National Cancer Institute , the Sidney Kimmel Center for Prostate and Urologic Cancers, and David H. Koch through the Prostate Cancer Foundation.
Prostate cancer patients who received hypofractionated radiation therapy reported that their quality of life, as well as bladder and bowel function were at similar levels before and after RT, according to new research. Prostate cancer patients who received hypofractionated radiation therapy reported that their quality of life, as well as bladder and bowel function were at similar levels before and after RT, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.
Dan Fogelberg spent the last days of his life speaking out about prostate cancer and raising awareness about screenings using his personal three year journey as an example. In December 2007, Fogelberg succumbed to the disease, said Junior Vasquez, co-host and music director of the Lubbock Friends of Fogelber event.
One in seven men will be diagnosed with prostate cancer during his lifetime, and one in 36 of them will die from it. "Eddie Check" offers free PSA screenings for prostate cancer One in seven men will be diagnosed with prostate cancer during his lifetime, and one in 36 of them will die from it.
Balding middle-aged men have a greater chance of getting aggressive prostate cancer later in life than those with a full head of hair, say researchers who suggest the result may one day help doctors predict the disease. The study reviewed the cases of 39,070 men 55 to 74 years old who were asked to use a pictorial to identify their own baldness at age 45. Those with moderate hair loss on the front and crown of the head were 39 percent more at risk of getting fast-growing, aggressive prostate cancer, the study found.
A specific kind of baldness is linked to aggressive prostate cancer, finds a new study published in the Journal of Clinical Oncology . Researchers analyzed the self-reported hair-loss patterns from 39,000 men enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial and found that men who recalled having male pattern baldness - characterized by a receding hairline and thinning hair on the crown - at age 45 had a 40% increased risk of developing aggressive prostate cancer when they got older compared to men who weren't balding.
A comparison of five-year sexual function outcomes, as reported by patients treated with external beam radiotherapy versus combination EBRT plus brachytherapy, indicates that the utilization of vessel-sparing radiation therapy makes cure possible without compromising long-term sexual function, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. The study examined the patient-reported outcomes of 91 men with prostate cancer who received MRI-guided, vessel-sparing radiation at University of Michigan Providence Cancer Institute.
SMOOTH RIDING TODAY.. FOR DOZENS OF CLASSIC CARS ALONG DODGE TODAY. THE SHINY RIDES DRAW ATTENTION TO MORE THAN JUST HORSEPOWER..
The analysis, published today in the American Journal of Pathology , found that prostate cancer patients who carry certain genetic mutations have a 91 percent chance of their cancer recurring. This research was funded by the National Institutes of Health , American Cancer Society and University of Pittsburgh Cancer Institute .
BGI, the world's largest genomics organization, based in China, and The Vancouver Prostate Centre , a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including personalized oncology. The collaboration, the first between BGI and any Canadian research institution, will change the landscape of genomic and translational research across Canada and benefit patients worldwide.
Kristine Warner wanted an eye-catching way to encourage men to talk to their doctors about the complicated, controversial subject of prostate cancer screening. The finger in question, of course, is the one a physician puts up a man's rectum to feel for cancer in his prostate gland.
High-risk prostate cancer patients who receive radiation therapy and an 18-month course of androgen deprivation therapy recover a normal testosterone level in a shorter amount of time compared to those who receive a 36-month course of ADT, thus resulting in a better quality of life and without detriment to long-term outcomes, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. Researchers analyzed data from 561 patients with high-risk prostate cancer from a multi-center, randomized phase III trial in Canada .
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
Scientists have identified 23 new genetic variants that indicate a person's risk of prostate cancer, enabling them to explain up to a third of inherited risk. Screening for prostate cancer has seen huge advances, with scientists recently identifying 23 new genetic variants associated with risk of the disease.
Updated: Tue Sep 16, 2014 09:43 am
Copyright © 2014 Topix LLC